Effect of pregabalin in treatment of uremic restless leg syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017072312685N9

Enrollment

Registered

2017-08-20

Start date

2017-08-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless leg syndrome. Other specified extrapyramidal and movement disorders

Interventions

Intervention 1: pregabaline treatment with starting dose 50 mg once daily and gradually titrated up to 100 mg once daily it tolerated for a priod of 12 week. Intervention 2: The control group are trea

Treatment - Drugs

Placebo

pregabaline treatment with starting dose 50 mg once daily and gradually titrated up to 100 mg once daily it tolerated for a priod of 12 week.

The control group are treated with placebo for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of ESRD; restless leg syndrome; signing of the informed consent. Exclusion criteria:anemia; iron deficiency; treatment with other restless leg syndrome specific drugs; hypercalcemia; hypocalcemia; sensitivity to pregabalin; patient who reject cooprate for follow up

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of restless legs syndrome symptoms. Timepoint: Beginning and end of study. Method of measurement: International restless legs syndrome study group rating scale(IRLS)questionnaire.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: The entire study priod. Method of measurement: By patients report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shilan Haseli

Internal Medicine Department of Kermanshah Faculty of Medicine

Shilan.haseli@gmail.com+98 83 3427 6330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026